> That is an especially pressing challenge in the development of new antibiotics, because a lack of economic incentives has caused pharmaceutical companies to pull back from the search for badly needed treatments. Each year in the U.S., drug-resistant bacteria and fungi cause more than 2.8 million infections and 35,000 deaths, with more than a third of fatalities attributable to C. diff, according to the the Centers for Disease Control and Prevention.
How big does the market have to be to commercially viable for research and development? Nearly 3M potential patients at a couple hundred dollars per course is nearing a $1B/year.
How big does the market have to be to commercially viable for research and development? Nearly 3M potential patients at a couple hundred dollars per course is nearing a $1B/year.